|
| 36383926 | Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. | J Clin Oncol | 2023 |
| 37479706 | Obesity-associated changes in molecular biology of primary breast cancer. | Nat Commun | 2023 |
| 37310797 | Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG). | Oncologist | 2023 |
| 36977286 | Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy. | J Clin Oncol | 2023 |
| 37075276 | Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. | J Clin Oncol | 2023 |
| 37225592 | Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohort. | Breast | 2023 |
| 35061525 | Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. | J Clin Oncol | 2022 |
| 35636341 | Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. | Breast | 2022 |
| 35101364 | Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. | J Geriatr Oncol | 2022 |
| 34861376 | Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. | Ann Oncol | 2022 |
| 34082017 | Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. | Ann Oncol | 2021 |
| 33721561 | 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. | Lancet Oncol | 2021 |
| 34301749 | Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. | Clin Cancer Res | 2021 |
| 34312396 | Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. | NPJ Breast Cancer | 2021 |
| 32795875 | Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial. | Eur J Cancer | 2020 |
| 32083990 | Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. | J Clin Oncol | 2020 |
| 32719399 | Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial. | Commun Biol | 2020 |
| 30790095 | Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. | Clin Rheumatol | 2019 |
| 30899086 | Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. | Br J Cancer | 2019 |
| 30972577 | Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. | Clin Rheumatol | 2019 |
| 29092024 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Ann Oncol | 2018 |
| 28043761 | The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. | Joint Bone Spine | 2017 |
| 28243468 | Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study. | RMD Open | 2017 |
| 26925253 | Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. | RMD Open | 2016 |
| 26966919 | Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. | Clin Exp Rheumatol | 2016 |
| 26063454 | Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). | Arthritis Res Ther | 2015 |
| 26228643 | Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. | BMC Musculoskelet Disord | 2015 |
| 24410774 | Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. | BMC Musculoskelet Disord | 2014 |
| 21914628 | Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. | Ann Rheum Dis | 2011 |
| 22151924 | Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. | Arthritis Res Ther | 2011 |
| 20100351 | Are joint and soft tissue injections painful? Results of a national French cross-sectional study of procedural pain in rheumatological practice. | BMC Musculoskelet Disord | 2010 |